Clarification for “Reporting a suspected adverse reaction”: the point beginning “Record the product, timing and a factual description of…” belongs to …

Limit of the answer in “Source-review index: unresolved, documented and corrected”: “Use clear evidence-status labels and dates, and link…” is an exce…

Quote a short relevant phrase and identify the official leaflet version without sharing private details. Ask a pharmacist to explain how it applies to…

Case 92 — Redacting a review: which details should stay private? · documentation exercise Limit of the answer in “Redacting a review: which details sh…

Case 15 — Reading a leaflet without treating a forum as a prescription Method note for “Reading a leaflet without treating a forum as a prescription”:…

Clarification for “Recall notices: verify the product and jurisdiction”: the point beginning “Use the official regulator or manufacturer notice and…” …

Case 23 — Delivery feedback is not a medicine-quality assessment Correction note for “Delivery feedback is not a medicine-quality assessment”: retain …

Case 20 — A source review checklist that separates evidence from reassurance Limit of the answer in “A source review checklist that separates evidence…

Case 7 — Review chronology: order date is different from delivery evidence Clarification for “Review chronology: order date is different from delivery…

Bring an accurate list of medicines and supplements to a pharmacist and state the question and relevant symptoms directly. This forum template cannot …

Case 11 — Review moderation: evidence without doxxing A disputed review includes private contact details. How can evidence be retained responsibly? Ex…

Use opaque redactions in a flattened exported copy, then reopen that copy and inspect it at full size. Do not rely on a translucent marker or a revers…

Limit of the answer in “Reporting a suspected adverse reaction”: “Record the product, timing and a factual description of…” is an excerpt from the dis…